N-(3,4,5-Trimethoxybenzylideneamino)guanidine acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(3,4,5-Trimethoxybenzylideneamino)guanidine acetate
• 英文别名: acetic acid;2-[(E)-(3,4,5-trimethoxyphenyl)methylideneamino]guanidine
• 化学式: C₂H₄O₂*C₁₁H₁₆N₄O₃
• 分子量: 312.326
• InChiKey: YPSPMYQBQKBDCR-JSSTZBRYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.62
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE<br/>[FR] DERIVES DE GUANIDINE ET LEUR UTILISATION DANS LA PRODUCTION D'UN MEDICAMENT DESTINE A BLOQUER LES XANTHINE OXYDASES/DESHYDROGENASES
  申请人：MELACURE THERAPEUTICS AB

  公开号：WO2001025192A1

  公开（公告）日：2001-04-12

  The present invention relates to guanidine derivatives and pharmaceutically acceptable acid salts thereof. The invention further relates to pharmaceutical preparations containing said compounds, and the use of said compounds for treatment of any type of condition where the expression of xanthine oxidase/xanthine dehydrogenase enzymes is involved. The invention particularly relates to the use of these compounds in the preparation of a medicament for enhancing the survical of a transplanted cell, organ or tissue, or cell, organ or tissue to be transplanted.

  本发明涉及胍衍生物及其药用酸盐。本发明还涉及含有该化合物的制药制剂，以及使用该化合物治疗涉及黄嘌呤氧化酶/黄嘌呤脱氢酶酶表达的任何类型疾病的用途。本发明特别涉及使用这些化合物制备增强移植细胞、器官或组织的存活或待移植的细胞、器官或组织的药物。
• Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
  申请人：——

  公开号：US20040024060A1

  公开（公告）日：2004-02-05

  The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof. 1

  本发明涉及使用一般式（I）化合物作为黑色素皮质激素受体的配体和/或治疗黑色素皮质激素系统疾病的方法：其中X为H或OH；R1、R2、R3、R4和R5相同或不同，选择自氢，卤素，1至5个碳原子的烷基，电子给体基团，如1-5个碳原子的烷氧基或羟基，电子受体基团，选择自氰基，硝基，三氟烷基或酰胺；烷基氨基，苯甲酰氧基，硝基氧基，苯基或磺酸基；以及其药理活性盐。
• THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS
  申请人：Melacure Therapeutics AB

  公开号：EP1313461A2

  公开（公告）日：2003-05-28
• USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS
  申请人：Lundstedt Torbjörn

  公开号：US20110015437A1

  公开（公告）日：2011-01-20

  The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.
• METHOD FOR TREATING ARTHRITIS
  申请人：LUNDSTEDT Torbjörn

  公开号：US20120178820A1

  公开（公告）日：2012-07-12

  The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.